Cumberland Pharmaceuticals Enhances Sancuso Digital Presence with New Educational Website — Cumberland Pharmaceuticals Inc.

Event summary

Cumberland Pharmaceuticals launched a new website for Sancuso (granisetron transdermal system) on March 17, 2026, featuring educational resources for chemotherapy-induced nausea and vomiting (CINV).
The website includes comprehensive product information, healthcare provider resources, a physician insights resource center, and patient education materials.
Sancuso is the only FDA-approved skin patch for preventing CINV in patients receiving moderately and/or highly emetogenic chemotherapy.
The website is designed with simplified navigation and mobile-optimized features for easy access to information.

The big picture

Cumberland Pharmaceuticals' launch of the new Sancuso website aligns with the broader trend of pharmaceutical companies leveraging digital platforms to enhance patient and healthcare provider education. This strategic move aims to strengthen the company's position in the oncology supportive care market, particularly in the prevention of chemotherapy-induced nausea and vomiting. The website's focus on providing comprehensive resources underscores the growing importance of digital tools in improving patient outcomes and streamlining healthcare delivery.

What we're watching

Market Differentiation: How Cumberland's enhanced digital presence will differentiate Sancuso in the competitive CINV prevention market.
Patient Adoption: The pace at which patients and healthcare providers adopt the new educational resources and integrate them into CINV management.
Regulatory Compliance: Whether the website's educational content will face any regulatory scrutiny or require adjustments to comply with healthcare advertising guidelines.